Drug intelligence / Profile preview

OX472

Development stage: Preclinical
Lead developer: Orexo
Modality: Peptides
Administration: Intranasal

Overview

OX472 is an investigational intranasal powder formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by Orexo for the treatment of type 2 diabetes and obesity. The drug utilizes Orexo's proprietary AmorphOX technology, which produces an amorphous composite powder designed for high chemical and physical stability, rapid dissolution, and improved bioavailability. Preclinical data suggests that OX472 may offer significantly higher bioavailability compared to oral semaglutide (Rybelsus) and provides a needle-free alternative to injectable GLP-1 therapies, potentially improving patient adherence and eliminating the need for refrigeration.

Other names: intranasal semaglutideAmorphOX semaglutide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on OX472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OX472.

Explore the full profile